“Progression free survival (… higher in both rituximab arms compared to IFRT … in the R and R + IFRT groups vs. 2.3 years in the IFRT one (p Conclusions: In conclusion, patients who underwent … long-term control of the disease despite a significantly poorer prognostic profile at time of diagnosis.”